Oncology (all articles)
RCT | Pembrolizumab plus chemotherapy in advanced endometrial cancer
3 Apr, 2023 | 13:48h | UTCPembrolizumab plus Chemotherapy in Advanced Endometrial Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
Original Article: Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer https://t.co/dTyV1zTO0I
#SGOMtg @SGO_org pic.twitter.com/R3FDom8pVY— NEJM (@NEJM) March 29, 2023
RCT | Dostarlimab for primary advanced or recurrent endometrial cancer
3 Apr, 2023 | 13:46h | UTCDostarlimab for Primary Advanced or Recurrent Endometrial Cancer – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary:
Dostarlimab Plus Chemotherapy Elicits PFS Benefit in Recurrent Endometrial Cancer – OncLive
Cohort Study | Long-term quality of life and functional outcome of patients with rectal cancer following a watch-and-wait approach
3 Apr, 2023 | 13:31h | UTCLong-term Quality of Life and Functional Outcome of Patients With Rectal Cancer Following a Watch-and-Wait Approach – JAMA Surgery (free for a limited period)
Invited Commentary: Guiding Patients Through a “Watch-and-Wait” Approach for Rectal Cancer—Understanding the Functional Outcomes – JAMA Surgery (free for a limited period)
Related:
Commentary on Twitter
Results of this study suggest that patients with rectal cancer who were observed by a watch-and-wait approach had good quality of life, with some patients reporting bowel and sexual dysfunction. https://t.co/zaK3bjJA8n
— JAMA Surgery (@JAMASurgery) March 31, 2023
RCT | Comparing exemestane dose regimens in early-stage ER+ breast cancer
31 Mar, 2023 | 13:37h | UTCEfficacy of Alternative Dose Regimens of Exemestane in Postmenopausal Women With Stage 0 to II Estrogen Receptor–Positive Breast Cancer: A Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Exemestane 25 mg (Exe) 3x/week (TIW) in compliant patients is comparable to daily dosing in reducing circulating estradiol; a weekly dose was less effective. Toxicity similar in all arms, suggesting Exe TIW may be used in breast cancer prevention. https://t.co/2NugINVrim #BCS
— JAMA Oncology (@JAMAOnc) March 23, 2023
M-A | Impact of axillary lymph node dissection and sentinel lymph node biopsy on upper limb morbidity in breast cancer patients
31 Mar, 2023 | 13:30h | UTC
Review | Management of immune related endocrinopathies following immune checkpoint inhibitor therapy for cancer
31 Mar, 2023 | 13:23h | UTCRelated:
RCT | Ganitumab added to chemotherapy did not improve outcomes in patients with metastatic Ewing sarcoma
30 Mar, 2023 | 14:16h | UTCRandomized Phase III Trial of Ganitumab With Interval-Compressed Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma: A Report From the Children’s Oncology Group – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary: Ganitumab Provides No Benefit in Metastatic Ewing Sarcoma – Cancer Therapy Advisor
Study shows a slight breast cancer risk increase with progestogen-only birth control, comparable to combined oral methods
29 Mar, 2023 | 13:35h | UTCSummary: A UK study and meta-analysis examined breast cancer risk linked to hormonal contraceptives, emphasizing progestagen-only contraceptives in premenopausal women. Utilizing a nested case-control design with the Clinical Practice Research Datalink (CPRD), a primary care database, the study included 9,498 women under 50 diagnosed with invasive breast cancer between 1996 and 2017, and 18,171 closely matched controls. The meta-analysis merged CPRD findings with 12 observational studies on progestagen-only preparations.
The results revealed that current or recent use of combined oral contraceptives, oral progestagen-only contraceptives, injectable progestagen, and progestagen intrauterine devices all led to a similar increase in breast cancer risk. The 15-year absolute excess risk associated with five years of oral combined or progestagen-only contraceptive use ranged from 8 per 100,000 users aged 16-20 to 265 per 100,000 users aged 35-39. The study concluded that both contraceptive types were linked to a slight breast cancer risk increase, and these risks must be weighed against the benefits of contraceptive use during childbearing years.
News Release: Study finds similar association of progestogen-only and combined hormonal contraceptives with breast cancer risk – PLOS
Phase 2b RCT | Liposomal irinotecan plus fluorouracil/leucovorin for patients with previously treated metastatic biliary tract cancer
29 Mar, 2023 | 13:14h | UTCTreatment With Liposomal Irinotecan Plus Fluorouracil and Leucovorin for Patients With Previously Treated Metastatic Biliary Tract Cancer: The Phase 2b NIFTY Randomized Clinical Trial – JAMA Oncology (link to abstract – $ for full-text)
Commentary on Twitter
Final analysis of NIFTY trial demonstrates significant improvement of PFS & OS with use of nal-IRI plus 5-FU/LV compared to 5-FU/LV in patients with previously treated advanced biliary tract cancer. https://t.co/WrZ3GtXYxP #GICSM pic.twitter.com/BqxSbBG9dv
— JAMA Oncology (@JAMAOnc) March 23, 2023
RCT | Effects of Docetaxel as a radiosensitizer in patients with head and neck cancer, unsuitable for cisplatin-based chemoradiation
29 Mar, 2023 | 13:05h | UTCResults of Phase III Randomized Trial for Use of Docetaxel as a Radiosensitizer in Patients With Head and Neck Cancer, Unsuitable for Cisplatin-Based Chemoradiation – Journal of Clinical Oncology (link to abstract – $ for full-text)
Editorial: Good Radiosensitizer Hunting – Journal of Clinical Oncology
Commentaries:
Docetaxel Added to Radiation Provides DFS, OS Benefit in Cisplatin-Ineligible HNSCC – OncLive
Consensus Paper | Diagnosis and treatment of anticancer drug-induced interstitial lung disease
29 Mar, 2023 | 13:04h | UTC
ChatGPT vs. NCI: analyzing the quality of cancer information on myths and misconceptions
28 Mar, 2023 | 15:00h | UTCNews Release: Looking for cancer information: Can ChatGPT be counted on? – Huntsman Cancer Institute
Consensus Statement | Management of vaginal intraepithelial neoplasia
28 Mar, 2023 | 14:37h | UTC
Review | Systemic therapy in HR+/HER2- early stage & metastatic breast cancer management
28 Mar, 2023 | 14:34h | UTC
Expanding Organ Usage: UK study finds organs from patients with a primary brain tumor are a viable option
27 Mar, 2023 | 13:27h | UTCSummary: A national cohort study in the UK investigated the risk of cancer transmission from deceased donors with primary brain tumors to organ recipients. The study found no cases of brain tumor transmission among 778 transplants from 282 donors with primary brain tumors, including 262 from donors with high-grade tumors. Organ transplant survival was equivalent to that in matched controls, and some organs from donors with high-grade tumors were less likely to be transplanted.
The results suggest that the risk of cancer transmission in transplants from deceased donors with primary brain tumors is lower than previously thought. Furthermore, the study indicated that donors with brain tumors provided good-quality organs with favorable risk markers and excellent transplant outcomes. Some organs from donors with high-grade tumors were underutilized, indicating a possible aversion by transplant clinicians or patients to use these organs.
These findings imply that it may be possible to safely expand organ usage from donors with primary brain tumors without negatively impacting outcomes, potentially benefiting many patients waiting for a transplant. Although this might lead to a slight rise in transplant numbers in the UK, the findings may hold particular significance for nations with stricter guidelines, such as the United States. The study’s findings can help transplant clinicians discuss the risks and benefits of accepting organ offers from such donors.
Outcomes of ST elevation myocardial infarction in patients with cancer: a nationwide study
27 Mar, 2023 | 13:12h | UTCOutcomes of ST elevation myocardial infarction in patients with cancer: a nationwide study – European Heart Journal – Quality of Care and Clinical Outcomes (free for a limited period)
Commentary on Twitter
Cancer and #STEMI – a worrisome combination of higher short- and long-term mortality, and bleeding risk. https://t.co/kHvhGP0PBE #EHJQCCO #cardiotwitter @cpgale3 @diogoasantosfer pic.twitter.com/SfjyizoJvQ
— European Society of Cardiology Journals (@ESC_Journals) March 26, 2023
Review | Neoadjuvant therapy for pancreatic cancer
27 Mar, 2023 | 13:02h | UTCNeoadjuvant therapy for pancreatic cancer – Nature Reviews Clinical Oncology (free for a limited period)
Study reveals overuse of surveillance colonoscopy in older adults with limited life expectancy
23 Mar, 2023 | 13:11h | UTCSummary: This study investigated the association between estimated life expectancy, surveillance colonoscopy findings, and follow-up recommendations among older adults. The study utilized data from the New Hampshire Colonoscopy Registry and included adults over 65 who underwent colonoscopy for surveillance after prior polyps.
Life expectancy was estimated using a validated prediction model and categorized into three groups: less than 5 years, 5 to less than 10 years, and 10 or more years.
Out of the 9,831 adults included in the study, 8% had advanced polyps or CRC. Among the 5,281 patients with available recommendations, 86.9% were advised to return for a future colonoscopy. Surprisingly, 58.1% of older adults with less than 5 years of life expectancy were also recommended to return for future surveillance colonoscopy.
The study concluded that many older adults with limited life expectancy are still recommended for future surveillance colonoscopy. This data could help refine decision-making about pursuing or stopping surveillance colonoscopy in older adults with a history of polyps.
Article: Association of Life Expectancy With Surveillance Colonoscopy Findings and Follow-up Recommendations in Older Adults – JAMA Internal Medicine (link to abstract – $ for full-text)
JAMA Patient Page: What Should I Know About Stopping Routine Cancer Screening?
Commentary on Twitter
Findings suggest that recommending against future surveillance colonoscopy in older adults with low-risk colonoscopy findings and/or limited life expectancy should be considered more frequently than is currently practiced. https://t.co/7jKpYyuZON
— JAMA Internal Medicine (@JAMAInternalMed) March 13, 2023
Guideline | Merkel cell carcinoma
23 Mar, 2023 | 12:48h | UTC
Guidelines for Gastric Cancer | An evidence-based, multidisciplinary approach
22 Mar, 2023 | 13:33h | UTC
Guidelines for post polypectomy colonoscopic surveillance
22 Mar, 2023 | 13:31h | UTCRelated:
USPSTF Statement: Start colorectal cancer screening at 45 years for most patients.
ACG Clinical Guidelines: Start colorectal cancer screening at 45
RCT | Comparable 5-year relapse-free survival for laparoscopic vs. open distal gastrectomy in advanced gastric cancer
22 Mar, 2023 | 13:27h | UTCSummary: The JLSSG0901 randomized clinical trial aimed to compare the 5-year survival outcomes of laparoscopy-assisted distal gastrectomy (LADG) and open distal gastrectomy (ODG) with D2 lymph node dissection for locally advanced gastric cancer.
The study involved 507 patients from 37 institutes in Japan. The primary endpoint was 5-year relapse-free survival. The results showed that the 5-year relapse-free survival rates were 73.9% and 75.7% for the ODG and LADG groups, respectively, confirming the noninferiority of LADG, and no significant differences were observed in severe postoperative complications between the two groups.
The study concluded that LADG with D2 lymph node dissection, when performed by qualified surgeons, was proven noninferior to ODG, and could become a standard treatment for locally advanced gastric cancer.
Article: Five-Year Survival Outcomes of Laparoscopy-Assisted vs Open Distal Gastrectomy for Advanced Gastric Cancer: The JLSSG0901 Randomized Clinical Trial – JAMA Surgery (link to abstract – $ for full-text)
Related:
Commentary on Twitter
Study results provide robust evidence suggesting that laparoscopic gastrectomy for locally advanced gastric cancer may be an appropriate treatment approach when performed by skilled surgeons. https://t.co/Dvnzk5YI9u pic.twitter.com/GDCdT4DJhp
— JAMA Surgery (@JAMASurgery) March 15, 2023
RCT | Hyperfractionation vs. standard fractionation in IMRT for patients with locally advanced recurrent nasopharyngeal carcinoma
22 Mar, 2023 | 13:12h | UTCHyperfractionation compared with standard fractionation in intensity-modulated radiotherapy for patients with locally advanced recurrent nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial – The Lancet (link to abstract – $ for full-text)
Suggested guidelines for the treatment of mycosis fungoides in countries with limited resources
21 Mar, 2023 | 13:29h | UTC
Guidelines for the management of people with cutaneous squamous cell carcinoma in situ (Bowen disease)
21 Mar, 2023 | 13:27h | UTC